Deals: Page 8
-
Getty Images
Novartis wagers billions of dollars on PTC Huntington’s drug
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.
By Jacob Bell • Dec. 2, 2024 -
Kevin Dietsch / Staff via Getty Images
Pharma hopes Trump will bring change to the FTC. They may be disappointed.
Some in the drug industry expect more lenient merger enforcement under a second Trump administration. One former regulator argues that might not be the case.
By Kelly Bilodeau • Nov. 27, 2024 -
Jacob Bell/BioPharma Dive
Sarepta rebuilds drug pipeline with Arrowhead deal
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and another $325 million in equity investment.
By Ned Pagliarulo • Nov. 27, 2024 -
Permission granted by Roche
Roche to buy cell therapy developer Poseida for $1B
The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing share price on Monday.
By Jacob Bell • Nov. 26, 2024 -
Courtesy of Novartis
Novartis wagers more than $1B on gene therapies for the nervous system
In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like Duchenne muscular dystrophy and myotonic dystrophy type 1.
By Jacob Bell • Updated Nov. 21, 2024 -
Thomas Lohnes via Getty Images
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit Therapeutics’ ivonescimab.
By Jonathan Gardner • Nov. 13, 2024 -
Getty Images
Novo inks Ascendis deal to develop long-acting GLP-1, other metabolic drugs
Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of drug-enhancing technology.
By Jonathan Gardner • Nov. 4, 2024 -
Leon Neal via Getty Images
GSK to pay $300M to license drug it sees as potential lupus treatment
The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease.
By Ned Pagliarulo • Oct. 29, 2024 -
Courtesy of AbbVie
AbbVie to acquire a J&J-backed brain drugmaker for $1.4B
The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is that it could create "another formidable competitor” to drug delivery specialist Denali Therapeutics.
By Jacob Bell • Updated Oct. 28, 2024 -
Getty Images
Lyell, in search of a turnaround, to buy cell therapy startup ImmPact
The deal will give Lyell a dual-targeting CAR-T candidate for blood cancers. Relatedly, Lyell will also end development of two current pipeline programs.
By Ben Fidler • Oct. 24, 2024 -
Courtesy of Sanofi
Sanofi moves ahead with CD&R deal for stake in consumer business
Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.
By Delilah Alvarado • Oct. 21, 2024 -
Courtesy of Viatris
Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe
The deal offers Lexicon a cash infusion of $25 million as the company tries to broaden use of the heart failure and diabetes medication.
By Kristin Jensen • Oct. 17, 2024 -
Elizabeth Regan/BioPharma Dive
Lundbeck to buy brain drug developer Longboard for $2.6B
The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product.
By Jacob Bell • Oct. 14, 2024 -
Courtesy of Sanofi
Sanofi may have found a buyer for its consumer health business
The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.
By Jacob Bell • Oct. 11, 2024 -
Courtesy of Sanofi
Sanofi’s rare disease drug finds yet another home
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
By Jacob Bell • Oct. 4, 2024 -
Courtesy of Roche
Roche turns to a startup in search for new breast cancer drugs
The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.
By Jonathan Gardner • Sept. 30, 2024 -
Permission granted by Roivant Sciences
Roivant dermatology subsidiary to be acquired by Organon
The deal hands Organon a psoriasis and eczema cream called Vtama, while Roivant will get more cash to fund its R&D plans.
By Kristin Jensen • Sept. 18, 2024 -
Mario Tama via Getty Images
Judge orders J&J to pay Auris investors more than $1B for merger violations
J&J did not provide Auris Health with resources to achieve regulatory milestones after acquiring the robotics company in 2019, the judge found.
By Ricky Zipp • Sept. 6, 2024 -
Getty Images
Startup Halda raises $126M to advance new type of targeted cancer therapy
Technology inspired by work at Yale researcher Craig Crews’ labs will be used to target prostate and breast cancer in early clinical trials.
By Jonathan Gardner • Updated Aug. 13, 2024 -
Courtesy of Merck & Co.
Immune resetMerck bets $700M on an antibody drug’s potential in immune diseases
The deal hands Merck a cancer medicine already in human testing, but that the company sees as a potential treatment for autoimmune conditions, too.
By Ben Fidler • Aug. 9, 2024 -
Getty Images
Emerging biotechWith pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships
Recent data from J.P. Morgan indicates early-stage startups are getting smaller upfront payments in alliances than a few years ago, a trend industry insiders attribute to weaker leverage in deal talks.
By Gwendolyn Wu • Aug. 9, 2024 -
Permission granted by Recursion Pharmaceuticals
Recursion to absorb Exscientia in ‘techbio’ deal
The two AI drug discovery firms, which have each lost most of their value since going public, believe their complementary skills can better speed the development of new medicines.
By Kristin Jensen • Aug. 8, 2024 -
Courtesy of Boehringer Ingelheim
Boehringer adds to cancer drug pipeline with deal for startup Nerio
The pharma company will pay up to $1.3 billion to acquire San Diego-based Nerio and its research into novel immune checkpoint inhibitors.
By Ned Pagliarulo • July 29, 2024 -
Brian Tucker/BioPharma Dive
Private biotech M&A surges amid difficult IPO market
Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.
By Gwendolyn Wu • July 22, 2024 -
Permission granted by Boehringer Ingelheim
Boehringer cuts price of Humira biosimilar in bid to build use
The German drugmaker will offer a 92% discount on a copycat version of Humira for people who pay cash for the drug through GoodRx.
By Jonathan Gardner • July 18, 2024
Previous
